- InMode’s fourth-quarter revenue was $97.9 million, which missed the estimate of $108.4 million and declined by 23% year-over-year.
- The company’s adjusted earnings per share (EPS) came in at 42 cents, falling short of the 54-cent estimate and well below the 71 cents reported a year ago.
- InMode’s gross margin for the quarter was 79%, compared to an 84% margin in the previous year, and under the estimated 81% for this quarter.
- Moshe Mizrahy, CEO of InMode, cited unexpected challenges in the aesthetics industry and broader macroeconomic factors as reasons for the weaker results.
- Despite the results, InMode is considering returning additional capital to shareholders by the end of the year, leveraging its strong free cash flow and confidence in the business.
- Analyst recommendations for InMode include 3 buy ratings and 4 hold ratings, with no sell ratings.
A look at Inmode Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using the Smartkarma Smart Scores have indicated a positive long-term outlook for Inmode. The company scores well in terms of resilience, with a top score of 5. This indicates that Inmode is well-positioned to withstand market fluctuations and challenges. Additionally, Inmode shows strength in both value and growth factors, with scores of 3 for each. This suggests that the company offers good value to investors and has potential for future growth. Momentum, with a score of 3, also indicates that Inmode has a solid upward trend in the market.
InMode Ltd. develops innovative medical devices that utilize cutting-edge radio-frequency technology. The company’s products cater to both patients and healthcare professionals, showcasing a commitment to enhancing medical treatments. With a global customer base, Inmode is poised for continued success in the medical device industry, supported by favorable Smartkarma Smart Scores in resilience, value, growth, and momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
